937-439-6186

Research

DCND is committed to furthering science and medicine to help patients. Getting involved in research can help the medical community develop new drugs and treatments that can help improve the quality of life for patients. The overall goal is to know as much as we can about a disease so we can better treat it. By getting involved in research, you can help others in the same situation and possibly get access to cutting edge treatment not available to the public yet.

 

Now enrolling in studies for:

  • Migraine
  • Multiple Sclerosis
  • Myasthenia Gravis
  • Alzheimer’s/Dementia

Are you a candidate?

How research works

Our research team and your provider will determine what study best lines up with your diagnosis. Our team will review the research study in detail with you and your participation is completely voluntary. Some studies reimburse you for travel. Every study is different on what kind of information or exam is required. 

Alzheimer's/Dementia

Cassava (Simufilam)

This study is for patients with mild-to-moderate Alzheimer’s disease, age 50-87. Study requires a study partner; someone who spends a minimum of 10 hours per week with the patient.

Learn more about this study here: https://www.cassavasciences.com/simufilam 

Migraine

Chronic Migraine:

ABP-20001

Patients with chronic migraine, age 18 and above.  Patients must keep a daily eDiary (app that will be downloaded onto their phone) of their migraines.

 

Multiple Sclerosis

CORRONA MS REGISTRY. All MS patients ≥18 years old who are NOT currently enrolled in clinical trials.

VERISMO. New starts (within 30 days) of ANY disease modifying therapy for MS.

COVID-US
A study to assess response to COVID-19 vaccine in participants with MS treated with ofatumumab 20 mg subcutaneously.

MASTER-2. Relapsing Remitting Multiple Sclerosis. ≥ 18 years old; Previously on IV MS medication, starting Mavenclad

Myasthenia Gravis

ALXN-MG-501
An observational study in patients diagnosed with General Myasthenia Gravis, age 18 and above, who have ever received treatment with complement C5 inhibition therapies (Soliris or Ultomiris).

Essential Tremor

ELATE

Botox vs. placebo in patients with moderate-to-severe upper limb essential tremor, age 18-80.

Talk with our research team

ARE YOU A CANDIDATE? FIND OUT NOW.

(937) 424-3033

research@dcndinc.com

1975 Miamisburg-Centerville Rd. Centerville, OH 45459